CTLA4 and neoplasm: Combined with tumor stage, TMB, CTLA4, and PD-L1 expression, MSI status, and TME phenotype, CuproptosisScore can serve as an effective predictive schedule for prognosis and contribute to performing patient stratification for the determination of immunotherapy regimen in colorectal cancer patients.